Major Depressive Disorder Clinical Trials in Houston, Texas

9 studies are recruiting for major depressive disorder in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

   This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   DM Clinical Research, Houston, Texas

   Locations

   69 in total

   Run by

   Intra-Cellular Therapies, Inc.

   See if you can join NCT05850689 on ClinicalTrials.gov

2. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Houston, Texas

   Locations

   120 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06966401 on ClinicalTrials.gov

3. Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium

   The objective of this study is to evaluate the safety, tolerability, and preliminary efficacy of the Motif eXternally powered Cortical Stimulation (XCS) System when used as indicated for treatment-resistant depression (TRD).

   Stage

   Not phased

   Ages

   22 to 85

   Site

   UTHealth Houston, Houston, Texas

   Locations

   4 in total

   Run by

   Motif Neurotech, Inc.

   See if you can join NCT07594483 on ClinicalTrials.gov

4. Study of ALTO-300 in MDD

   The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

   Stage

   Phase 2

   Ages

   18 to 70

   Site

   Site 275, Houston, Texas

   Locations

   75 in total

   Run by

   Alto Neuroscience

   See if you can join NCT05922878 on ClinicalTrials.gov

5. Cortical rTMS as a Treatment for Depression

   Depression is a leading cause of disability worldwide with a 19% lifetime prevalence in the United States. Dysfunctional reward processing is one of the core features of depression. Common treatments of depression include psychological therapies (e.g., cognitive behavioral therapy), medication (e.g…

   Stage

   Not phased

   Ages

   18 to 64

   Site

   The Menninger Clinic, Houston, Texas

   Run by

   Baylor College of Medicine

   See if you can join NCT05487911 on ClinicalTrials.gov

6. Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression

   The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome. Previous research focused exclusively on KET-induced gamma band potentiation …

   Stage

   Phase 1

   Ages

   21 to 45

   Site

   Wells Medicine, Houston, Texas

   Locations

   2 in total

   Run by

   Texas A&M University

   See if you can join NCT06480201 on ClinicalTrials.gov

7. Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

   The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are: Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a l…

   Stage

   Phase 2

   Ages

   18 to 64

   Site

   Baylor College of Medicine, Psychiatry and Behavioral Sciences, Houston, Texas

   Locations

   34 in total

   Run by

   Syndeio Biosciences, Inc

   See if you can join NCT06547489 on ClinicalTrials.gov

8. Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Houston, Texas

   Locations

   18 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06786624 on ClinicalTrials.gov

9. Neurobehavioral Therapy For Epilepsy And Major Depressive Disorder

   The purpose of this study is to examine the feasibility and acceptability of an online group Neuro-behavioral Therapy (NBT) with text messaging intervention for Veterans with epilepsy and major depressive disorder (MDD).

   Stage

   Not phased

   Ages

   18 and older

   Site

   Michael E. DeBakey VA Medical Center, Houston, Texas

   Locations

   2 in total

   Run by

   The University of Texas Health Science Center, Houston

   See if you can join NCT06695767 on ClinicalTrials.gov